Fairvalue-Calculator Fairvalue-Calculator
EN DE

Zentalis Pharmaceuticals, Inc (ZNTL) Fair Value & Analysis

Healthcare · US · Market cap $283M

Price$3.97
Fair Value$2.53
Upside-36.3%
Quality95/100
Evidence: Low Range $1.67 – $3.17

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Zentalis Pharmaceuticals, Inc (ZNTL) currently trades at $3.97, while our model-based Fair Value estimate is $2.53 — implying the stock looks roughly 36.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Zentalis Pharmaceuticals, Inc (ZNTL) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $2.53 versus a price of $3.97 — about −36% (overvalued). Model-based estimate, not financial advice.
What is the fair value of ZNTL?
Our 21-model fair value for Zentalis Pharmaceuticals, Inc is $2.53 (as of Jun 25, 2026), built from audited fundamentals. The current price is $3.97.
What is the quality score of ZNTL?
Zentalis Pharmaceuticals, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.